Skip to Main Content

Paper Details

The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
BMJ Open
14
2015
PARTICIPANTS, nAMD, neovascular AMD, neovascular age-related macular degeneration, patient, patients, ranibizumab
Aged, Aged, 80 and over, Angiogenesis Inhibitors, Cost-Benefit Analysis, Eye, Female, Health Care Costs, Humans, Macular Degeneration, Male, Markov Chains, Middle Aged, Models, Economic, Monte Carlo Method, Outcome Assessment, Health Care, Practice Patterns, Physicians', Prospective Studies, Quality-Adjusted Life Years, Ranibizumab, State Medicine, United Kingdom, Visual Acuity
Author NameAffiliation
Thomas ButtInstitute of Ophthalmology, University College London
Aaron LeeMoorfields Eye Hospital
Cecilia S LeeMoorfields Eye Hospital, UK University of Washington
Adnan TufailInstitute of Ophthalmology, University College London, UK Moorfields Eye Hospital
  • 1 - 4

Datasets

Release 1.2